Biocon

In News

Biocon Biologics Inc. - Reuters

Reuters - Oct 14, 2026

Genentech Drops Lawsuit Against Biocon Over Perjeta Biosimilar - Bloomberg Law News

Bloomberg Law News - Oct 14, 2026

Watch Biocon Chair: AI in Clinical Trials Is the Holy Grail - Bloomberg.com

Bloomberg.com - Oct 15, 2026

Biocon Announces U.S. Commercial Launch of Yesafili™, a Biosimilar to Regeneron’s Eylea® 2 mg - Business Wire

Business Wire - Aug 03, 2026

Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy - Reuters

Reuters - Oct 14, 2026

Biocon Enters Global Settlement And License Agreement With Genentech For Pebrilzo - TradingView

TradingView - Oct 14, 2026

Biocon Secures Licensed Launch Dates For Pebrilzo Following Genentech Patent Settlement - BW Healthcare

BW Healthcare - Oct 15, 2026

Biocon (NSEI:BIOCON) Stock Gets Fair Value Bump As Analysts Weigh Execution And Earnings Visibility - Yahoo Finance

Yahoo Finance - Sep 19, 2026

Biocon's Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach - Morningstar

Morningstar - Sep 22, 2026

Biocon's Pertuzumab Biosimilar Earns CHMP Nod Under EMA's New Tailored Pathway - BioPharm International

BioPharm International - Sep 22, 2026

Biocon Ltd. Share Price Today - Biocon Ltd. Stock Price Live NSE/BSE - CNBC TV18

CNBC TV18 - Oct 16, 2026

Biocon Announces Peer-Reviewed Data Supporting Yesafili in Diabetic Macular Edema - Eyewire+

Eyewire+ - Sep 07, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment